Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin
- 1 October 2006
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (4) , 424-430
- https://doi.org/10.1038/sj.bjp.0706875
Abstract
Background and purpose: The types of hepatic microsomal cytochrome P450 (CYP) isozymes responsible for the metabolism of metformin in humans and rats have not been published to date. Therefore, a series of experiments using various inducers and inhibitors of CYP isozymes was conducted to find out what types of CYP isozymes are involved in the metabolism of metformin in rats.Experimental approach: Metformin at a dose of 100 mg kg−1was administered intravenously to rats. The rats were pretreated with CYP inducers such as 3‐methylcholanthrene, orphenadrine, isoniazid, and dexamethasone (major inducers of CYP1A1/2, 2B1/2, 2E1, and 3A1/2, respectively, in rats), or CYP inhibitors such as SKF‐525 (a non‐specific inhibitor of CYP isozymes), and sulfaphenazole, quinine, and troleandomycin (major inhibitors of CYP2C11, 2D1, and 3A1/2, respectively, in rats). The time‐averaged non‐renal clearance (CLNR) of metformin was compared with that of controls.Key results: In rats pretreated with dexamethasone, the CLNRwas significantly faster (57% increase) than for the controls. In rats pretreated with SKF‐525‐A, sulfaphenazole, quinine, and troleandomycin, the CLNRwas significantly slower (24.3, 62.9, 77.6, and 78.7% decrease, respectively) than for the controls. However, the CLNRvalues did not significantly different in the rats pretreated with 3‐methylencholanthrene, orphenadrine, and isoniazid compared with the controls.Conclusions and implications: Our data suggest that metformin was metabolized mainly via CYP2C11, 2D1, and 3A1/2 in rats. This result could contribute to understanding of the possible changes in metformin pharmacokinetics in disease models where CYP2C11 and/or 3A1/2 are altered.British Journal of Pharmacology(2006)149, 424–430. doi:10.1038/sj.bjp.0706875Keywords
This publication has 28 references indexed in Scilit:
- Dose-Independent Pharmacokinetics of Metformin in Rats: Hepatic and Gastrointestinal First-Pass EffectsJournal of Pharmaceutical Sciences, 2006
- Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein−calorie malnutritionJournal of Pharmaceutical Sciences, 2004
- Upregulation of cytochromes P450 2B in rat liver by orphenadrineBritish Journal of Pharmacology, 2003
- Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA‐8159, using an equilibrium dialysis techniqueBiopharmaceutics & Drug Disposition, 2000
- Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 1996
- Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutritionJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Effects of Phenobarbital and 3-Methylcholanthrene Pretreatment on the Pharmacokinetics and Pharmacodynamics of Furosemide in RatsJournal of Pharmaceutical Sciences, 1991
- New Calculation method of mean Total Body Clearance of Drugs and its Application to Dosage RegimensJournal of Pharmaceutical Sciences, 1980
- Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curveJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjectsJournal of Pharmacokinetics and Biopharmaceutics, 1977